Similar articles

• EPO--one year later. Effects of EPO on nutritional status in CRF.

  Schiro KB. Schiro KB. Nephrol News Issues. 1990 May;4(5):26, 34. Nephrol News Issues. 1990. PMID: 2348876 No abstract available.
• EPO (epoetin) approval stirs cost concern in Congress.

  Wagner M. Wagner M. Mod Healthc. 1989 Jun 9;19(23):4. Mod Healthc. 1989. PMID: 10293460 No abstract available.
• The use of recombinant human erythropoietin (EPO) to correct the anemia of end-stage renal disease: a progress report.

  Adamson W, Egrie JC, Browne JK, Downing MR, Eschbach W. Adamson W, et al. Behring Inst Mitt. 1988 Aug;(83):188-92. Behring Inst Mitt. 1988. PMID: 3071336 Clinical Trial.
• [Treatment of renal anemia using synthetic human erythropoietin].

  Blumberg A, Zehnder C. Blumberg A, et al. Ther Umsch. 1988 Dec;45(12):895-9. Ther Umsch. 1988. PMID: 3065970 Review. German. No abstract available.
• [Erythropoietin: its biological properties and clinical use].

  Ermolenko VM, Nikolaev AIu. Ermolenko VM, et al. Ter Arkh. 1990;62(11):141-5. Ter Arkh. 1990. PMID: 2094979 Review. Russian. No abstract available.